Loading...

PE anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1.2
PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
  • XMG1.2
    PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
505807 25 µg 32€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505808 100 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Wang H, et al. 2013. J Immunol. 191:6010. PubMed
  2. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  3. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  4. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  7. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  8. Zhang H, et al. 2022. Eur J Immunol. 52:978. PubMed
  9. Jia JJ, et al. 2022. J Leukoc Biol. 112:157. PubMed
  10. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  11. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  12. Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed
  13. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  14. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  15. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  16. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  17. Xu H, et al. 2022. Aging Dis. 13:1875. PubMed
  18. Tan TCJ, et al. 2022. Nat Commun. 13:7796. PubMed
  19. Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed
  20. Chan L, et al. 2022. Cells. 12: . PubMed
  21. Liu H, et al. 2023. Cell Death Differ. :. PubMed
  22. Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed
  23. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  24. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  25. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  26. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  27. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  28. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  29. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  30. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  31. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  32. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  33. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  34. Li D, et al. 2023. Ann Med. 55:2189295. PubMed
  35. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  36. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  37. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  38. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  39. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  40. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  41. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  42. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  43. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  44. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  45. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  46. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  47. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  48. Chen Y, et al. 2020. Virol Sin. . PubMed
  49. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  50. Chen, B., Huang, Z., et al. 2025. Invest Ophthalmol Vis Sci. 66(15),16. PubMed
  51. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  52. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  53. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  54. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  55. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  56. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  57. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  58. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  59. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  60. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  61. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  62. Wang X, et al. 2018. Int Immunopharmacol. 56:249. PubMed
  63. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  64. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  65. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  66. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  67. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  68. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  69. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  70. Dong L, et al. 2021. Cancer Cell. . PubMed
  71. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  72. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  73. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  74. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  75. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  76. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  77. Herman JD, et al. 2021. Nat Commun. 12:6853. PubMed
  78. Galeano Niño JL, et al. 2020. J Cell Sci. . PubMed
  79. Saito S, et al. 2020. Nutrients. 12:. PubMed
  80. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  81. Michel M, et al. 2012. Proc Natl Acad Sci U S A. 109:17459. PubMed
  82. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  83. Koenecke C, et al. 2012. J Immunol. 189:2890. PubMed
  84. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  85. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  86. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  87. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  88. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  89. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  90. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  91. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  92. Kuttke M, et al. 2022. Front Immunol. 13:695576. PubMed
  93. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  94. Subbiah J, et al. 2022. NPJ Vaccines. 7:68. PubMed
  95. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  96. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  97. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  98. Wan Y, et al. 2014. Vaccine. 41:241. PubMed
  99. Sandrock I, et al. 2015. PLoS One. 10: 0145010. PubMed
  100. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  101. Probst P, et al. 2017. Cancer Res. 77:3644. PubMed
  102. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  103. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  104. An J, et al. 2022. iScience. 25:103570. PubMed
  105. Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed
  106. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  107. Shami A, et al. 2015. Sci Rep. 5: 13904. PubMed
  108. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  109. Hegde S, et al. 2020. Cancer Cell. 37(3):289-307. PubMed
  110. Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed
  111. Chen D, et al. 2022. J Neuroinflammation. 19:112. PubMed
  112. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  113. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  114. Cho K, Hill A 2008. J Immunol Methods. 330:137. PubMed
  115. Condotta S, et al. 2015. J Immunol. 195: 116 - 125. PubMed
  116. Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed
  117. Hundt M, et al. 2009. J Immunol. 183:1685. PubMed
  118. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  119. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  120. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  121. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  122. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  123. Sartorius R, et al. 2015. EMBO Mol Med. 7: 973 - 988. PubMed
  124. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  125. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  126. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  127. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  128. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  129. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  130. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  131. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  132. Ma Y, et al. 2013. J Immunol. 190:5588. PubMed
  133. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  134. QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed
  135. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  136. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  137. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  138. Tian X, et al. 2022. J Cell Mol Med. 26:693. PubMed
  139. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  140. Galeano Niño JL, et al. 2020. J Cell Sci. 133:00:00. PubMed
  141. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  142. Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed
  143. Kraus Z, et al. 2008. J Immunol. 181:7800. PubMed
  144. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  145. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  146. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  147. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  148. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  149. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  150. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  151. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  152. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  153. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  154. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  155. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  156. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  157. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  158. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  159. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  160. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  161. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  162. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  163. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  164. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  165. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  166. Zhang J, et al. 2018. Nature. 553:91. PubMed
  167. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  168. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  169. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  170. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  171. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  172. Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed
  173. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  174. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  175. Li H, et al. 2021. Front Immunol. 12:739605. PubMed
  176. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  177. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  178. Miao W, et al. 2020. J Immunol. 1486:204. PubMed
  179. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  180. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  181. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  182. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  183. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  184. Johnson RM, et al. 2021. Front Immunol. 11:614697. PubMed
  185. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  186. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  187. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  188. Tomaru U et al. 2019. Cell reports. 26(3):639-651 . PubMed
  189. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  190. Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed
  191. Zhang X, et al. 2020. J Cancer. 11:648. PubMed
  192. Molgora M, et al. 2020. Cell. 182:886. PubMed
  193. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  194. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  195. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  196. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  197. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  198. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  199. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  200. Li H, et al. 2022. iScience. 25:104481. PubMed
  201. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  202. Zhang X, et al. 2021. Front Pharmacol. 12:706748. PubMed
  203. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  204. Zhao K, et al. 2021. Biomed Res Int. 7619849:2020. PubMed
  205. Gaylo A, et al. 2013. Transpl Immunol. 20:163. PubMed
  206. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  207. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  208. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  209. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  210. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  211. Zheng Y, et al. 2022. Transl Res. :. PubMed
  212. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  213. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  214. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  215. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  216. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  217. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  218. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  219. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  220. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  221. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  222. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
RRID
AB_315401 (BioLegend Cat. No. 505807)
AB_315402 (BioLegend Cat. No. 505808)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All IFN-γ Reagents Request Custom Conjugation
Description Clone Applications
Alexa Fluor® 700 anti-mouse IFN-γ XMG1.2 ICFC
APC/Cyanine7 anti-mouse IFN-γ XMG1.2 ICFC
GoInVivo™ Purified anti-mouse IFN-γ XMG1.2 ELISA Capture,ELISPOT Capture,CyTOF®,Neut,ICFC,IHC,WB
APC/Fire™ 750 anti-mouse IFN-γ XMG1.2 ICFC
APC anti-mouse IFN-γ XMG1.2 ICFC
Biotin anti-mouse IFN-γ XMG1.2 ELISA Detection,ELISPOT Detection,ICFC
FITC anti-mouse IFN-γ XMG1.2 ICFC
PE anti-mouse IFN-γ XMG1.2 ICFC
Purified anti-mouse IFN-γ XMG1.2 ELISA Capture,CyTOF®,IHC,WB
Alexa Fluor® 488 anti-mouse IFN-γ XMG1.2 ICFC
Alexa Fluor® 647 anti-mouse IFN-γ XMG1.2 ICFC
Pacific Blue™ anti-mouse IFN-γ XMG1.2 ICFC
PerCP/Cyanine5.5 anti-mouse IFN-γ XMG1.2 ICFC
PE/Cyanine7 anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 421™ anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 650™ anti-mouse IFN-γ XMG1.2 ICFC
Ultra-LEAF™ Purified anti-mouse IFN-γ XMG1.2 ELISA Capture,ELISPOT Capture,CyTOF®,Neut,ICFC,IHC,WB
Brilliant Violet 711™ anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 785™ anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 605™ anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 510™ anti-mouse IFN-γ XMG1.2 ICFC
Purified anti-mouse IFN-γ (Maxpar® Ready) XMG1.2 ELISA Capture,CyTOF®
PE/Dazzle™ 594 anti-mouse IFN-γ XMG1.2 ICFC
Spark NIR™ 685 anti-mouse IFN-γ XMG1.2 ICFC
Spark UV™ 387 anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 750™ anti-mouse IFN-γ XMG1.2 ICFC
TotalSeq™-C1526 anti-mouse IFN-γ Antibody XMG1.2 ICPG
Spark PLUS UV395™ anti-mouse IFN-γ XMG1.2 ICFC
Go To Top Version: 2    Revision Date: 12/11/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account